Skip to content
Comparison

NAD+ vs Epithalon

NAD+ and Epithalon are commonly compared for anti-aging peptide framework ranking by evidence maturity. NAD+ is usually favored for rank #1 for metabolic-energy support evidence breadth, while Epithalon is often preferred for rank #2 for longevity-pathway peptide experimentation. This head-to-head analysis focuses on mechanism, trial outcomes, dosing context, evidence quality, regulatory status, and practical decision points for safer YMYL decision-making.

Quick Answer

For anti-aging peptide framework ranking by evidence maturity, the better choice depends on your primary endpoint. NAD+ is stronger when the priority is pragmatic metabolic anti-aging support. Epithalon is stronger when the priority is experimental longevity-cycle protocols. Use evidence grade, dose intensity, access constraints, and tolerability profile to match therapy to the patient profile rather than choosing by hype alone.

Head-to-Head Comparison

CriteriaNAD+Epithalon
Primary mechanismCoenzyme replenishment strategy for mitochondrial and metabolic pathwaysSynthetic tetrapeptide investigated for pineal and telomerase-related aging pathways
Strongest clinical signalSignals for improved cellular energetics and metabolic resilienceLongevity and immune-aging signals in preliminary human and animal studies
Typical dosing contextIV, IM, SC, or oral precursor protocols vary widelyCommon protocols use short cycles (e.g., 5-10 mg daily for 10-20 days)
AdministrationClinic infusions/injections or oral support stacksSubcutaneous or intramuscular injection
Evidence quality gradeModerate mechanistic evidence; heterogeneous clinical outcomesPreliminary; significant need for modern large RCTs
Regulatory statusNot an FDA-approved disease-specific peptide therapyNot FDA-approved
Side-effect burdenGenerally tolerated; protocol quality and formulation matterGenerally tolerated in reported use, but data depth is limited
Cost/access contextHigh for infusion-heavy protocolsModerate cycle-based peptide cost
Best candidate profileEnergy/fatigue and metabolic-support strategiesUsers targeting longevity-oriented experimental protocols
Main limitationOutcome heterogeneity and protocol standardization gapsEvidence maturity below mainstream geroscience interventions
Best use case in this comparisonpragmatic metabolic anti-aging supportexperimental longevity-cycle protocols

When to Choose Each

Choose NAD+

Best for pragmatic metabolic anti-aging support.

Choose Epithalon

Best for experimental longevity-cycle protocols.

Verdict

If the main goal is pragmatic metabolic anti-aging support, NAD+ is usually the better first-line choice. If the main goal is experimental longevity-cycle protocols, Epithalon is typically the better fit. Reassess outcomes at 8-16 weeks with objective metrics, then adjust only when response, safety, or adherence data justify it. In high-risk populations, physician-guided personalization matters more than any generic ranking.

References

  1. NAD+ metabolism and its roles in cellular processes during ageing (2018)PubMed
  2. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults (2021)PubMed
  3. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging (2013)PubMed
  4. Effect of oral nicotinamide mononucleotide (NMN) on plasma NMN concentration and safety in healthy Japanese men (2020)PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

Large, established platform with strong physician network
Compounded semaglutide available where branded shortages exist
Easy async consult — no video call required
Does not offer a wide range of peptides beyond GLP-1s
Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

Broadest peptide therapy menu of any major telehealth provider
Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
Repair peptides including BPC-157 and TB-500
Higher starting price due to comprehensive programs
More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

Competitive pricing starting at $149/mo
Dedicated health coach included in program
Strong clinical protocols with lab-work integration
Narrower peptide offering — GLP-1s only
Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

Insurance navigation support for medication coverage
Evidence-based one-year program with structured milestones
Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
Annual program commitment required
Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

One of the more affordable monthly program fees
Strong community and peer support features
Certified health coaches with regular check-ins
Medication billed separately from program fee — total cost can be higher
Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Frequently Asked Questions

Which has stronger evidence for anti-aging peptide framework ranking by evidence maturity — NAD+ or Epithalon?
NAD+ is graded as moderate mechanistic evidence; heterogeneous clinical outcomes evidence in this context, while Epithalon is graded as preliminary; significant need for modern large rcts. In practice, strength depends on whether you prioritize pragmatic metabolic anti-aging support or experimental longevity-cycle protocols. Favor the option with endpoint data closest to your primary goal, and avoid extrapolating beyond studied populations.
Can NAD+ and Epithalon be combined or sequenced?
Sometimes, but only with clinician oversight. A common framework is to start with one agent, track objective response for 8-16 weeks, then switch or sequence if outcomes plateau or tolerability is poor. Combination protocols may increase both cost and adverse-effect complexity, so they should be justified by clear endpoint-based rationale.
What should be monitored before and during treatment?
Baseline assessment should include diagnosis confirmation, comorbidity risk, and contraindications. During therapy, monitor target outcomes (symptoms, body composition, labs), adverse effects, and adherence burden. For endocrine/metabolic strategies, periodic glucose, lipids, organ function, and indication-specific labs help keep risk proportional to expected benefit.